Effects of Valsartan on cardiac function, ventricular remodeling and matrix metalloproteinases in patients with CHF

ZHANG Tian; JIN Zhao; BAI Xiao-jun

doi:10.3969/j.issn.1672-5301.2017.08.019

Abstract：Objective To investigate the clinical effect of Valsartan in patients with CHF and the effects of Valsartan on ventricular remodeling and matrix metalloproteinases.Methods 108 patients with CHF who were treated in our hospital from January 2014 to January 2016 were selected,SPSS 16 software was used to generate the random number table,which was divided into observation group (basic treatment ± Valsartan) and control group(basic treatment),each with 54 cases,the course of treatment was 2 months,compared the clinical efficacy of the two groups of patients,ventricular remodeling index,serum levels of matrix metalloproteinase(MMP) levels.Results After treatment,LVEF (48.6±4.2)％ in the observation group was higher than that in the control group (45.1±4.7)％(P＜0.05),LVEDd,LVESd,LVMI and MWS were [(52.3±3.6)mm,(41.1±4.1)mm,(132.1±6.8)g/m2,(355.0±18.7)dmes×103/cm2],respectively,lower than control group [(54.1±4.3)mm,(43.3±3.6)mm,(135.2± 7.0)g/m2,(369.5 ±21.0)dmes x 103/cm2] (P ＜0.05).The level of TIMP-1 (349.2±43.7) ng/ml in the observation group was higher than that in the control group (311.7±49.0)ng/ml (P＜0.05).MMP-1,MMP-9 [(73.0±11.6)ng/ml,(139.5-±27.0)ng/ml] in the observation group were lower than those in the control group [(82.6±14.1)ng/ml,(155.2±24.1)ng/ml] (P＜0.05).After treatment,the observation group was markedly effective 64.81％,effective 33.33％,invalid 1.85％,the control group markedly effective 48.15％,effective 46.30％,invalid 5.56％,the difference between the two groups was statistically significant (P＜0.05).Conclusion Valsartan treatment of patients with CHF can further improve the cardiac function and delay ventricular remodeling,the mechanism may be related to the decrease of serum matrix metalloproteinase.